Bone metabolism and the perimenopause: Overview, risk factors, screening, and osteoporosis preventive measures

Obstetrics and Gynecology Clinics of North America

Volumn 29, Issue 3, 2002, Pages 495-510

  Sayegh, Raja A ^a   Stubblefield, Phillip G ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DAIDZEIN; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GENISTEIN; ISOFLAVONE; PHYTOESTROGEN; PLACEBO; PRASTERONE; RALOXIFENE; VITAMIN D;

BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CLINICAL TRIAL; DRUG APPROVAL; DYSPEPSIA; ESTROGEN DEFICIENCY; FEMALE; FOOD DRUG INTERACTION; FRACTURE; HIGH RISK PATIENT; HORMONAL THERAPY; HOT FLUSH; HUMAN; LEG CRAMP; MENOPAUSE; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCORING SYSTEM; SCREENING TEST; SOYBEAN; THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

BONE AND BONES; BONE DENSITY; BONE RESORPTION; CLIMACTERIC; FEMALE; HUMANS; MASS SCREENING; OSTEOPOROSIS; RISK FACTORS;

EID: 0036739911     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(02)00012-8     Document Type: Review

References (94)

1. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis: its clinical features. JAMA 1941;116:2465-74.
2. Watts NB. Postmenopausal osteoporosis. Obstet Gynecol Surv 1999;54:532-8.
3. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445-8.
4. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(suppl 5):505S-11S.
5. Miller KK, Klibanski A. Clinical review 106: amenorrheic bone loss. J Clin Endocrinol Metab 1999;84:1775-83.
6. Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998;339:599-603.
7. Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999;84:3431-4.
8. Carlsen CG, Soerensen TH, Eriksen EF. Prevalence of low serum estradiol levels in male osteoporosis. Osteoporos Int 2000;11:697-701.
9. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996;11:1043-5.
10. Jaffe RB. Menopause and aging. In: Yen SSC, Jaffe RB, Barbieri RL, editors. Reproductive endocrinology: physiology, pathophysiology and clinical management. Philadelphia: WB Saunders; 1999. p. 307-10.
11. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997; 7:407-13.
12. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767-73.
13. World Health Organization. Assessment of fracture risks and its application to screening for postmenopausal osteoporosis. WHO technical report series. Geneva: WHO; 1994.
14. National Osteoporosis Foundation. Physicians guide to prevention and treatment of osteoporosis. Bell Mead, NJ: Exerpta Medica Inc; 1999.
15. Limpaphayom KK, Taechakraichana N, Jaisamrarn U, et al. Prevalence of osteopenia and osteoporosis in Thai women. Menopause 2001;8:65-9.
16. Augat P, Fuerst T, Genant HK. Quantitative bone mineral assessment at the forearm: a review. Osteoporos Int 1998;8:299-310.
17. Greenspan SL, Bouxsein ML, Melton ME, et al. Precision and discriminatory ability of calcaneal bone assessment technologies. J Bone Miner Res 1997;12:1303-13.
18. Nieves JW, Golden AL, Siris E, et al. Teenage and current calcium intake are related to bone mineral density of the hip and forearm in women aged 30-39 years. Am J Epidemiol 1995; 141:342-51.
19. NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994;272:1942-8.
20. Suarez FL, Adshead J, Fume JK, et al. Lactose maldigestion is not an impediment to the intake of 1500 mg calcium daily as dairy products. Am J Clin Nutr 1998;68:1118-22.
21. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995;333:1-4.
22. Wyshak G. Teenaged girls, carbonated beverage consumption, and bone fractures. Arch Pediatr Adolesc Med 2000;154:610-3.
23. Fuchs RK, Bauer JJ, Snow CM. Jumping improves hip and lumbar spine bone mass in prepubescent children: a randomized controlled trial. J Bone Miner Res 2001;16:148-56.
24. Vitamin D supplementation for northern native communities. Can Med Assoc J 1988;138: 229-30.
25. Lopez JM, Gonzalez G, Reyes V, et al. Bone turnover and density in healthy women during breastfeeding and after weaning. Osteoporos Int 1996;6:153-9.
26. Michaelsson K, Baron JA, Farahmand BY, et al. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet 1999;353:1481-4.
27. Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000;61:77-82.
28. Taechakraichana N, Limpaphayom K, Ninlagarn T, et al. A randomized trial of oral contraceptive and hormone replacement therapy on bone mineral density and coronary heart disease risk factors in postmenopausal women. Obstet Gynecol 2000;95:87-94.
29. Petitti DB, Piaggio G, Mehta S, et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 2000;95:736-44.
30. Cundy T, Cornish J, Roberts H, et al. Spinal bone density in women using depot medroxypro-gesterone contraception. Obstet Gynecol 1998;92(4 pt 1):569-73.
31. Scholes D, Lacroix AZ, Ott SM, et al. Bone mineral density in women using depot medroxy-progesterone acetate for contraception. Obstet Gynecol 1999;93:233-8.
32. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-6.
33. Storm D, Eslin R, Porter ES, et al. Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial. J Clin Endocrinol Metab 1998;83:3817-25.
34. Riggs BL, O'Fallon WM, Muhs J, et al. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res 1998;13:168-74.
35. Hunter D, Major P, Arden N, et al. A randomized controlled trial of vitamin D supplementation on preventing postmenopausal bone loss and modifying bone metabolism using identical twin pairs. J Bone Miner Res 2000;15:2276-83.
36. Felson DT, Zhang Y, Hannan MT, et al. Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995;142:485-92.
37. Sampson HW. Alcohol, osteoporosis, and bone regulating hormones. Alcohol Clin Exp Res 1997;21:400-3.
38. Turner RT. Skeletal response to alcohol. Alcohol Clin Exp Res 2000;24:1693-701.
39. Cooper C, Atkinson EJ, Wahner HW, et al. Caffeine does not affect the rate of gain in spine bone in young women. Osteoporos Int 1996;6:149-52.
40. Cooper C, Atkinson EJ, Wahner HW, et al. Is caffeine consumption a risk factor for osteoporosis? J Bone Miner Res 1992;7:465-71.
41. Kiel DP, Felson DT, Hannan MT, et al. Caffeine and the risk of hip fracture: the Framingham Study. Am J Epidemiol 1990;132:675-84.
42. Kiel DP, Zhang Y, Hannan MT, et al. The effect of smoking at different life stages on bone mineral density in elderly men and women. Osteoporos Int 1996;6:240-8.
43. Kiel DP, Baron JA, Anderson JJ, et al. Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. Ann Intern Med 1992;116:716-21.
44. Nelson ME, Fiatarone MA, Morganti CM, et al. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures: a randomized controlled trial. JAMA 1994;272: 1909-14.
45. Shaw JM, Snow CMS. Weighted vest exercise improves indices of fall risk in older women. J Gerontol A Biol Sci Med Sci 1998;53:M53-8.
46. Henneman PH, Wallace S. A review of prolonged use of oestrogens and androgens in post-menopausal and senile osteoporosis. Ann Intern Med 1957;100:715-23.
47. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9-16.
48. Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal oestrogens protect against fractures of hip and distal radius: a case-control study. Lancet 1979;2:705-9.
49. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987;317:1169-74.
50. Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
51. The writing group for the PEPI trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996;276: 1389-96.
52. Genant HK, Baylink DJ, Gallagher JC. Estrogens in the prevention of osteoporosis in postmenopausal women. Am J Obstet Gynecol 1989;161(6 pt 2):1842-6.
53. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
54. Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001;110:442-505.
55. Mosekilde L, Beck-Nielsen H, Sorensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women: results of the Danish Osteoporosis Prevention Study. Maturitas 2000;36:181-93.
56. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-7.
57. Utian WH, Schiff I. NAMS-Gallup survey on women's knowledge, information sources and attitudes to menopause and hormone replacement therapy. Menopause 1994;1:39-48.
58. Prestwood KM, Kenny AM, Unson C, et al. The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab 2000;85:4462-9.
59. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol 1999;94:330-6.
60. Achieving long-term continuance of menopausal ERT/HRT: consensus opinion of the North American Menopause Society. Menopause 1998;5:69-76.
61. Shoupe D. Androgens and bone: clinical implications for menopausal women. Am J Obstet Gynecol 1999;180(3 pt 2):S329-33.
62. Beardsworth SA, Kearney CE, Purdie DW. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. Br J Obstet Gynaecol 1999;106:678-83.
63. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498-505.
64. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 2000;97:4279-84.
65. Haden ST, Glowacki J, Hurwitz S, et al. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. Calcif Tissue Int 2000;66:414-8.
66. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282: 637-45.
67. Fugere P, Scheele WH, Shah A, et al. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 2000;182:568-74.
68. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical efidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
69. Cummings SR, Black DM, Thompson DE, et al. Effects of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
70. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24.
71. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85:3109-15.
72. Stock JL, Bell NH, Chesnut CH III, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103:291-7.
73. McClung MR, Geusens P, Miller PD, et al. Effect of Risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
74. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of residronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
75. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic; fractures study. PROOF Study Group. Am J Med 2000;109:267-76.
76. Downs RW Jr, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000;85:1783-8.
77. Maksymowych WP. Managing acute osteoporotic vertebral fractures with calcitonin. Can Fam Physician 1998;44:2160-6.
78. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
79. Pak CY, Sakhaee K, Adams-Huet B, et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995; 123:401-8.
80. Picherit C, Coxam V, Bennetau-Pelissero C. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr 2000;130:1675-81.
81. Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001;285:1482-8.
82. Cummings SR, Cauley JA, Palermo L, et al. Racial differences in hip axis lengths might explain racial differences in rates of hip fracture. Study of Osteoporotic Fractures Research Group. Osteoporos Int 1994;4:226-9.
83. Gilsanz V, Skaggs DL, Kovanlikaya A, Sayre J, Loro ML, Kaufman F, et al. Differential effect of race on the axial and appendicular skeletons of children. J Clin Endocrinol Metab 1998;83: 1420-7.
84. Rosen CJ, Bilezikian JP. Clinical review 123: anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001;86:957-64.
85. Neer RM, Amaud CD, Zanchetta JR, et al. Effects of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-41.
86. Wimalawansa SJ. Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents. J Clin Densitom 2000;3:187-201.
87. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000;85:720-6.
88. Greendale GA, Wells B, Marcus R, et al. How many women lose bone mineral density while taking hormone replacement therapy?: results from the postmenopausal Estrogen/Progestin interventions trial. Arch Intern Med 2000;160:3065-71.
89. Ongphiphadhankul B, Chanprasertyothin S, Payatikul P, et al. Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin Endocrinol (Oxf) 2000;52:581-5.
90. Albagha OM, McGuigan FE, Reid DM, et al. Estrogen receptor alpha gene polymorphisms and bone mineral density:haplotype analysis in women from the United Kingdom. J Bone Miner Res 2001;16:128-34.
91. Gennari L, Becherini L, Masi L, et al. Vitamin D and estrogen receptor allelic; variants in Italian postmenopausal women: evidence of multiple gene contribution to bone mineral density. J Clin Endocrinol Metab 1998;83:939-44.
92. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000;283:1318-21.
93. Arnaud CD. Osteoporosis: using "bone markers" for diagnosis and monitoring. Geriatrics 1996;51:24-30.
94. Delmas PD, Hardy P, Gamero P, et al. Monitoring individual response to hormone replacement therapy with bone markers. Bone 2000;26:553-60.